Long-acting opioids and cardiovascular diseases: Help or hindrance!

被引:6
|
作者
Mehta, Ankita [1 ]
Patel, Bhoomika M. [2 ,3 ]
机构
[1] Labcorp Cent Lab Serv Ltd Partnership, Bangalore, India
[2] Natl Forensic Sci Univ, Gandhinagar, India
[3] Natl Forensic Sci Univ, Sect 9, Gandhinagar 382007, Gujarat, India
关键词
Cardiac opioid receptors; Long -acting opioids (LAO); Methadone; Buprenorphine; Naltrexone; QTC INTERVAL PROLONGATION; PEPTIDE GENE-EXPRESSION; BAROREFLEX-MEDIATED BRADYCARDIA; TORSADES-DE-POINTES; RECEPTOR STIMULATION; CARDIAC-ARREST; PREJUNCTIONAL MODULATION; VENTRICULAR-ARRHYTHMIAS; NOCICEPTIN/ORPHANIN FQ; MYOCARDIAL-ISCHEMIA;
D O I
10.1016/j.vph.2023.107144
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Opioids are widely being used for chronic pain management, cough and diarrhea suppressants, anesthetic agents, and opioid de-addiction therapy. Opioid receptors, present in the central nervous system and peripheral tissues, are documented to regulate several cardiac functions through different signaling pathways. Long-acting opioids (LAO) have been successfully evaluated for their beneficial effects in various cardiovascular diseases viz. myocardial infarction, ischemic reperfusion injuries, atherosclerosis etc. However, on the other hand, several research studies pointed towards the harmful effects of LAOs which are mainly associated with QTc prolongation, torsade de pointes, ventricular arrhythmias, and cardiac arrest. This review shall familiarize readers with the benefits as well as the harmful effects of long-acting opioids in cardiovascular diseases. We have also provided an overview of cardiac opioid receptors, endogenous cardiac opioid peptides, and regulation of cardiovascular functions by central and cardiac opioid receptors.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Rates of adverse events of long-acting opioids in a state Medicaid program
    Hartung, Daniel M.
    Middleton, Luke
    Haxby, Dean G.
    Koder, Michele
    Ketchum, Kathy L.
    Chou, Roger
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (06) : 921 - 928
  • [22] Re: Systematic review of long-acting oral opioids - Authors' response
    Chou, R
    Helfand, M
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (03) : 195 - 195
  • [23] Comment: therapy switching in patients receiving long-acting opioids - Reply
    Oster, G
    Berger, A
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (10) : 1753 - 1753
  • [24] Considerations in guidelines development -: Titrating opioids and converting to long-acting agents
    Payne, R
    ONCOLOGY-NEW YORK, 1999, 13 (11A): : 581 - 586
  • [26] Daily Average Consumption of 2 Long-Acting Opioids and Coverage Decisions
    Mitchell, Matthew
    AMERICAN HEALTH AND DRUG BENEFITS, 2012, 5 (01): : 60 - 60
  • [28] THE UNDERSTANDING NSW LONG-ACTING OPIOIDS IN CUSTODY-TREATMENT STUDY
    Dunlop, Adrian J.
    Roberts, Jillian
    White, Bethany
    Haber, Paul S.
    Attia, John
    Oldmeadow, Christopher
    Searles, Andrew
    Cretikos, Michelle A.
    Mackson, Judith
    Attalla, Dena
    Murrell, Terry
    Doyle, Michael
    McEntyre, Elizabeth
    Brown, Libby
    Hussein, Hellal
    Howard, Mark
    Sequeira, Marcia
    Lintzeris, Nicholas
    DRUG AND ALCOHOL REVIEW, 2019, 38 : S43 - S43
  • [29] Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain
    Ray, Wayne A.
    Chung, Cecilia P.
    Murray, Katherine T.
    Hall, Kathi
    Stein, C. Michael
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (22): : 2415 - 2423
  • [30] Comment: therapy switching in patients receiving long-acting opioids - Reply
    Oster, G
    Berger, A
    Seifeldin, R
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) : 1325 - 1325